NEOVACS: Néovacs presented the latest results of its vaccine candidates targeting allergies during two international meetings – 06/10/2024 at 08:00

• May 29-31: EMBRN Conference –
  
  European Mast cell and Basophil Research Network
  
  of which
  
  Neovacs is
  
  Gold Sponsor
  

• May 31 – June 3: EAACI 2024 Congress –
  
  European Academy of Allergy and Clinical Immunology
  

Suresnes, June 10, 2024 – 8:00 a.m. CET – Néovacs (Euronext Growth Paris: ALNEV), a biopharmaceutical company at a preclinical stage developing new therapies for inflammatory and autoimmune diseases, announces that work on its IL-4/ therapeutic vaccines IL-13 and IgE were presented at two international meetings.

EMBRN Conference, Toulouse, France

Presentation titled:

Development of vaccines to treat allergic diseases

Speaker: Dr. Laurent Reber, Director of Research and Innovation

EAACI Congress, Valencia, Spain

Presentation titled:

A vaccine targeting IgE induces long-term protection against anaphylaxis in humanized mice

Speaker: Dr. Katia Lemdani, R&D Manager

The results presented at these two conferences demonstrate that the IgE vaccine induces long-term protection against allergy in humanized mouse models. Indeed, our results showed production of antibodies neutralizing the pathogenic activity of IgE up to one year after administration of the IgE vaccine in humanized mice, without notable adverse effects. This vaccination reduces circulating IgE and provides lasting protection against anaphylactic shock, the most severe clinical manifestation of allergy.

ABOUT NEOVACS

Néovacs is a French biotechnology company which conducts a dual activity of R&D and investment. Its own products are vaccine candidates developed from its kinoid® technology platform in lupus and allergies. The innovative approach uses the patient’s immune system to regulate harmful overproduction of proteins (active immunotherapy) such as IL-4/IL-13/IgE. At the same time, the Company uses its internal expertise to invest in innovative Biotech and Medtech companies with high potential.

For more information :

www.neovacs.fr

Warning :

The company Néovacs has set up (i) financing in the form of OCEANE-BSA with the company European High Growth Opportunities Securitization Fund, which, after receiving the shares resulting from the conversion or exercise of these instruments, n is not intended to remain a shareholder of the company, and (ii) financing in ORA which have all been transferred to a trust, which is now responsible for their equitization.

The shares resulting from the conversion or exercise of the above-mentioned securities are generally sold in the market at very short notice, which can create strong downward pressure on the share price. In the specific case of the trust, the shares are sold on the market according to the terms set out in the trust agreement.

Shareholders may suffer a loss of their invested capital due to a significant decrease in the value of the company’s stock, as well as significant dilution due to the number of securities issued to the company European High Growth Opportunities Securitization Fund and/or trust.

Investors are advised to be very vigilant before making the decision to invest (or remain invested) in the securities of the company admitted to trading which carries out such dilutive financing transactions, particularly when they are carried out successively. The company recalls that this dilutive financing operation is not the first that it has implemented.

© Copyright Actusnews Wire

Receive future company press releases free of charge by email by subscribing to www.actusnews.com